Roy D. Baynes's Net Worth
$2.47 Million
Who is Roy D. Baynes?
Roy D. Baynes has an estimated net worth of $2.47 Million. This is based on reported shares across multiple companies, which include Natera, Inc., Travere Therapeutics, Inc., and Atara Biotherapeutics, Inc..
SEC CIK
Roy D. Baynes's CIK is 0001680739
Past Insider Trading and Trends
2022 was Roy D. Baynes's most active year for acquiring shares with 10 total transactions. Roy D. Baynes's most active month to acquire stocks was the month of April. 2020 was Roy D. Baynes's most active year for disposing of shares, totalling 2 transactions. Roy D. Baynes's most active month to dispose stocks was the month of April. 2020 saw Roy D. Baynes paying a total of $31,746.00 for 54,368 shares, this is the most they've acquired in one year. In 2020 Roy D. Baynes cashed out on 2,600 shares for a total of $69,512.95, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Natera, Inc. (NTRA) Snapshot price: $112.9
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +0.79% | 124 |
—
|
—
| 15.81K |
Oct 25
| |||
Form 4
| +0.92% | 143 |
—
|
—
| 15.68K |
Jul 26
| |||
Form 4
| +23.57% | 2.96K |
—
|
—
| 15.54K |
Jun 28
| |||
Form 4
| +1.36% | 169 |
—
|
—
| 12.58K |
Apr 26
| |||
Form 4
| +1.76% | 215 |
$63.79 | $13,714.85 | 12.41K |
Jan 26
| |||
Form 4
| +2.71% | 322 |
$42.60 | $13,717.20 | 12.19K |
Oct 27
| |||
Form 4
| +2.27% | 264 |
$48.48 | $12,798.72 | 11.87K |
Jul 28
| |||
Form 4
| +31.05% | 2.75K |
—
|
—
| 11.61K |
Jun 30
| |||
Form 4
| +66.40% | 3.53K |
—
|
—
| 8.86K |
May 25
| |||
Form 4
| +4.48% | 228 |
$54.73 | $12,478.44 | 5.32K |
Apr 14
| |||
Form 4
| +6.52% | 312 |
$40.01 | $12,483.12 | 5.09K |
Jan 13
| |||
Form 4
| +6.10% | 275 |
$45.42 | $12,490.50 | 4.78K |
Oct 14
| |||
Form 4/A
| +8.26% | 344 |
—
|
—
| 4.51K |
Jul 8
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 8
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 27
| |||
Form 4
| +45.76% | 1.31K |
—
|
—
| 4.16K |
May 25
| |||
Form 4
|
∞
| 2.86K |
—
|
—
| 2.86K |
May 28
| |||
Form 4
|
—
|
0
|
$38.95 | -$37,766.95 |
0
|
Aug 7
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 12
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 24
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 14
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Travere Therapeutics, Inc. (TVTX) Snapshot price: $10.98
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +26.53% | 6.5K |
—
|
—
| 31K |
May 8
| |||
Form 4
| +22.50% | 4.5K |
—
|
—
| 24.5K |
May 17
| |||
Form 4
| +17.65% | 3K |
—
|
—
| 20K |
May 11
| |||
Form 4
| +21.43% | 3K |
—
|
—
| 17K |
May 14
| |||
Form 4
| +27.27% | 3K |
—
|
—
| 14K |
May 15
| |||
Form 4
| +22.22% | 2K |
—
|
—
| 11K |
May 8
| |||
Form 4
| +38.46% | 2.5K |
—
|
—
| 9K |
May 9
| |||
Form 4
| +62.50% | 2.5K |
—
|
—
| 6.5K |
May 17
| |||
Form 4
|
∞
| 4K |
—
|
—
| 4K |
Jul 19
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Atara Biotherapeutics, Inc. (ATRA) Snapshot price: $9.1465
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +89.13% | 20.5K |
—
|
—
| 43.5K |
Jun 23
| |||
Form 4
| +91.67% | 11K |
—
|
—
| 23K |
Jun 8
| |||
Form 4
| +200.00% | 8K |
—
|
—
| 12K |
Jun 16
| |||
Form 4
|
∞
| 4K |
—
|
—
| 4K |
Jun 27
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 11
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||